Genentech’s income was up 40.5% to $5.2...
- Share via
Genentech’s income was up 40.5% to $5.2 million in the third quarter. The South San Francisco biotechnology company said sales of the drug Protropin increased 92% to $23.8 million from the year-ago quarter. In addition, the company had a $333,000 tax benefit from an operating loss carryforward.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
